Menu
GeneBe

FOXL2

forkhead box L2, the group of Forkhead boxes

Basic information

Region (hg38): 3:138944223-138947137

Previous symbols: [ "BPES" ]

Links

ENSG00000183770NCBI:668OMIM:605597HGNC:1092Uniprot:P58012AlphaFoldGenCCjaxSfariGnomADPubmedClinVar

Phenotypes

GenCC

Source: genCC

  • blepharophimosis, ptosis, and epicanthus inversus syndrome (Strong), mode of inheritance: AD
  • blepharophimosis, ptosis, and epicanthus inversus syndrome (Definitive), mode of inheritance: AD
  • blepharophimosis, ptosis, and epicanthus inversus syndrome (Strong), mode of inheritance: AD
  • premature ovarian failure 3 (Limited), mode of inheritance: Unknown

Clinical Genomic Database

Source: CGD

ConditionInheritanceIntervention CategoriesIntervention/Rationale Manifestation CategoriesReferences
Blepharophimosis, epicanthus inversus, and ptosis; Premature ovarian failure 3ADObstetricAwareness may be beneficial to allow interventions such as preserving eggs in women with premature ovarian insufficiency (which is also reported in women with BPES)Craniofacial; Endocrine; Genitourinary; Obstetric; Ophthalmologic11175783; 12149404; 15962237; 16283882; 17089161; 19429596; 21325395

ClinVar

This is a list of variants' phenotypes submitted to ClinVar and linked to the FOXL2 gene.

  • Blepharophimosis, ptosis, and epicanthus inversus syndrome (77 variants)
  • not provided (64 variants)
  • Inborn genetic diseases (20 variants)
  • not specified (7 variants)
  • BLEPHAROPHIMOSIS, PTOSIS, AND EPICANTHUS INVERSUS, TYPE I (6 variants)
  • Premature ovarian failure 3 (5 variants)
  • BLEPHAROPHIMOSIS, PTOSIS, AND EPICANTHUS INVERSUS, TYPE II (4 variants)
  • FOXL2-related condition (3 variants)
  • Premature ovarian failure 3;Blepharophimosis, ptosis, and epicanthus inversus syndrome (2 variants)
  • Blepharophimosis, ptosis, and epicanthus inversus, type II with Duane retraction syndrome (1 variants)
  • Blepharophimosis, ptosis, and epicanthus inversus syndrome;Premature ovarian failure 3 (1 variants)
  • Premature ovarian insufficiency (1 variants)
  • Granulosa cell tumor (1 variants)
  • See cases (1 variants)

Variants pathogenicity by type

Statistics on ClinVar variants can assist in determining whether a specific variant type in the FOXL2 gene is commonly pathogenic or not.

In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.

Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.

Variant type Pathogenic Likely pathogenic VUS Likely benign Benign Sum
synonymous
1
clinvar
5
clinvar
5
clinvar
11
missense
3
clinvar
12
clinvar
42
clinvar
1
clinvar
2
clinvar
60
nonsense
16
clinvar
2
clinvar
18
start loss
1
clinvar
1
frameshift
37
clinvar
5
clinvar
42
inframe indel
5
clinvar
2
clinvar
3
clinvar
1
clinvar
11
splice donor/acceptor (+/-2bp)
0
splice region
0
non coding
1
clinvar
3
clinvar
4
Total 62 21 47 7 10

Highest pathogenic variant AF is 0.0000264

Variants in FOXL2

This is a list of pathogenic ClinVar variants found in the FOXL2 region.

You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.

Position Type Phenotype Significance ClinVar
3-138944666-C-CA Benign (Aug 22, 2019)1228805
3-138944973-G-T not specified • FOXL2-related disorder Benign (Oct 01, 2022)1685141
3-138944978-G-A FOXL2-related disorder Likely benign (May 11, 2020)3045061
3-138945277-TGGGCAGGAGACGCTGGGGCTCCGGAAAGAGACGAGCCCAGTAGAAAGCGCGCAGAGAGGCAGCTTCAGGCCAGGGGAGTGCAAGGTCACAGAGGTCAGGGAGGTGAGCACAGGAGGACATAAACTGAGGGGACAAAGAGGAGCGACAGGAGCTTAGGAAAGCGAAAAAGCACAGAGGGACCCTGGGCGCTGGCTCCAGAGGCGGGCCCAGAGGGTGTGAGGTCAGGCTGGCGGCGGCGTCGTCGGCTGCGACCGGGGCCGGCGTCGCGCGTCCCTGCATCCTCGCATCCGTCTGCACCGGCATGCGGTGGGCTCTCAGAGATCGAGGCGCGAATGCAGCGCGCCGGTCTTGCTGTCGTGGTCCCAGTAAGAGCAATGCATCATGGCGAGCTCGGGCTGCCGGGCACAAGCGAACTGCAGGCCCGGCGCACTGGTGGGCGCGGGCGCCGGGGGCGCGGCGGTGGCTGGGCTGGCAGGGCTGAGCTGGCCCGGCGGCGGCGCGGCGGCCCCGTGGTGCGGTGGGGCAGGCGGCGGTGCGGCGGCCGCGTGCAGATGGTGTGCGTGCGGATGCGGGTGGGGGTGCGGCGGAGGCGGGGGTGCGGCCGGCGGGCCTCCCAGGCCATTGTACGAGTTCACTACGCCGGGGGGCAGCGCCATGCTCTGCACGCGTGTGTACGGCCCGTACGAGGCGGCCGGGCCCGCCAGCCCCTTGACCACAGCGGCCGCGCCAGGGCTACCGGGGCCCGCGGCTGCAGCCGCAGCTGCTGCAGCCGC-GCGGCTGCAGCAGCTGCGGCTGCAGCCGCGGGCCCCGGTAGCCCTGGCGCGGCCGCTGTGGTCAAGGGGCTGGCGGGCCCGGCCGCCTCGTACGGGCCGTACACACGCGTGCAGAGCATGGCGCTGCCCCCCGGCGTAGTGAACTCGTACAATGGCCTGGGAGGCCCGCCGGCCGCACCCCCGCCTCCGCCGCACCCCCACCCGCATCCGCACGCACACCATCTGCACGCGGCCGCCGCACCGCCGCCTGCCCCACCGCACCACGGGGCCGCCGCGCCGCCGCCGGGCCAGCTCAGCCCTGCCAGCCCAGCCACCGCCGCGCCCCCGGCGCCCGCGCCCACCAGTGCGCCGGGCCTGCAGTTCGCTTGTGCCCGGCAGCCCGAGCTCGCCATGATGCATTGCTCTTACTGGGACCACGACAGCAAGACCGGCGCGCTGCATTCGCGCCTCGATCTCTGAGAGCCCACCGCATGCCGGTGCAGACGGATGCGAGGATGCAGGGACGCGCGACGCCGGCCCCGGTCGCAGCCGACGACGCCGCCGCCAGCCTGACCTCACACCCTCTGGGCCCGCCTCTGGAGCCAGCGCCCAGGGTCCCTCTGTGCTTTTTCGCTTTCCTAAGCTCCTGTCGCTCCTCTTTGTCCCCTCAGTTTATGTCCTCCTGTGCTCACCTCCCTGACCTCTGTGACCTTGCACTCCCCTGGCCTGAAGCTGCCTCTCTGCGCGCTTTCTACTGGGCTCGTCTCTTTCCGGAGCCCCAGCGTCTCCTGCCCA Pathogenic (Jun 01, 2021)1701464
3-138945608-G-A FOXL2-related disorder Uncertain significance (Jun 30, 2023)2631816
3-138945619-GC-G Blepharophimosis, ptosis, and epicanthus inversus syndrome Pathogenic (Jan 01, 2014)634965
3-138945622-G-T FOXL2-related disorder Benign (May 20, 2023)2890002
3-138945652-A-G not specified • FOXL2-related disorder Benign/Likely benign (Nov 09, 2023)435242
3-138945656-A-G Inborn genetic diseases Uncertain significance (Sep 14, 2023)2624406
3-138945670-G-A Likely benign (May 20, 2023)2188545
3-138945678-G-C not specified • Genetic non-acquired premature ovarian failure Likely pathogenic (Oct 01, 2019)134454
3-138945701-G-GGCGC Likely pathogenic (Jan 13, 2024)2709291
3-138945711-TG-T Blepharophimosis, ptosis, and epicanthus inversus syndrome Pathogenic (Nov 03, 2016)369938
3-138945724-C-CG Blepharophimosis, ptosis, and epicanthus inversus syndrome Pathogenic (Jan 01, 2015)634964
3-138945726-GGGGCGCGGCGGTGGCTGGGCTGGCAGGGCTGAGCTGGCCCGGCGGCGGCGCGGCGGCCCCGT-CGCCGCCGCC Blepharophimosis, ptosis, and epicanthus inversus syndrome Pathogenic (Jan 01, 2015)634984
3-138945728-G-A Inborn genetic diseases Uncertain significance (Nov 13, 2023)3096484
3-138945729-G-C Inborn genetic diseases Uncertain significance (Sep 29, 2022)2361547
3-138945734-G-GC Premature ovarian failure 3 Pathogenic (Jan 29, 2018)503493
3-138945739-G-GGCTGGGCTGGCAGGGCTGA Blepharophimosis, ptosis, and epicanthus inversus syndrome Pathogenic (Jan 01, 2015)162044
3-138945740-GC-G Blepharophimosis, ptosis, and epicanthus inversus syndrome Pathogenic (Nov 03, 2016)369937
3-138945749-G-C Inborn genetic diseases Uncertain significance (Nov 17, 2023)3096483
3-138945761-T-TGGCCCGGCGGC Blepharophimosis, ptosis, and epicanthus inversus syndrome Pathogenic (Nov 03, 2016)369936
3-138945763-G-GC BLEPHAROPHIMOSIS, PTOSIS, AND EPICANTHUS INVERSUS, TYPE I Pathogenic (Mar 01, 2003)4867
3-138945767-GGCGGCGGC-G Blepharophimosis, ptosis, and epicanthus inversus syndrome Pathogenic (May 28, 2019)634987
3-138945770-G-T Duane retraction syndrome Uncertain significance (Mar 13, 2024)3061823

GnomAD

Source: gnomAD

GeneTypeBio TypeTranscript Coding Exons Length
FOXL2protein_codingprotein_codingENST00000330315 12917
pLI Probability
LOF Intolerant
pRec Probability
LOF Recessive
Individuals with
no LOFs
Individuals with
Homozygous LOFs
Individuals with
Heterozygous LOFs
Defined p
0.8780.12100000.00
Z-Score Observed Expected Observed/Expected Mutation Rate Total Possible in Transcript
Missense1.761091750.6240.000008012370
Missense in Polyphen1340.5370.32069468
Synonymous-0.5218478.11.070.00000390822
Loss of Function2.4206.850.002.93e-790

LoF frequencies by population

EthnicitySum of pLOFs p
African & African-American0.000.00
Ashkenazi Jewish0.000.00
East Asian0.000.00
Finnish0.000.00
European (Non-Finnish)0.000.00
Middle Eastern0.000.00
South Asian0.000.00
Other0.000.00

dbNSFP

Source: dbNSFP

Function
FUNCTION: Transcriptional regulator. Critical factor essential for ovary differentiation and maintenance, and repression of the genetic program for somatic testis determination. Prevents trans- differentiation of ovary to testis through transcriptional repression of the Sertoli cell-promoting gene SOX9 (By similarity). Has apoptotic activity in ovarian cells. Suppresses ESR1-mediated transcription of PTGS2/COX2 stimulated by tamoxifen (By similarity). Is a regulator of CYP19 expression (By similarity). Participates in SMAD3-dependent transcription of FST via the intronic SMAD-binding element (By similarity). Is a transcriptional repressor of STAR. Activates SIRT1 transcription under cellular stress conditions. Activates transcription of OSR2. {ECO:0000250, ECO:0000269|PubMed:16153597, ECO:0000269|PubMed:19010791, ECO:0000269|PubMed:19429596, ECO:0000269|PubMed:19744555}.;
Disease
DISEASE: Blepharophimosis, ptosis, and epicanthus inversus syndrome (BPES) [MIM:110100]: A disorder characterized by eyelid dysplasia, small palpebral fissures, drooping eyelids and a skin fold curving in the mediolateral direction, inferior to the inner canthus. In type I BPSE (BPES1) eyelid abnormalities are associated with female infertility. Affected females show an ovarian deficit due to primary amenorrhea or to premature ovarian failure (POF). In type II BPSE (BPES2) affected individuals show only the eyelid defects. {ECO:0000269|PubMed:11175783, ECO:0000269|PubMed:11468277, ECO:0000269|PubMed:12400065, ECO:0000269|PubMed:12529855, ECO:0000269|PubMed:12630957, ECO:0000269|PubMed:12938087, ECO:0000269|PubMed:15257268, ECO:0000269|PubMed:16454982, ECO:0000269|PubMed:17089161, ECO:0000269|PubMed:18372316, ECO:0000269|PubMed:18484667, ECO:0000269|PubMed:18642388, ECO:0000269|Ref.2}. Note=The disease is caused by mutations affecting the gene represented in this entry. There is a mutational hotspot in the region coding for the poly-Ala domain, since 30% of all mutations in the ORF lead to poly-Ala expansions, resulting mainly in BPES type II.; DISEASE: Premature ovarian failure 3 (POF3) [MIM:608996]: An ovarian disorder defined as the cessation of ovarian function under the age of 40 years. It is characterized by oligomenorrhea or amenorrhea, in the presence of elevated levels of serum gonadotropins and low estradiol. {ECO:0000269|PubMed:12149404, ECO:0000269|PubMed:19429596}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
Pathway
SUMOylation of transcription factors;Post-translational protein modification;SUMO E3 ligases SUMOylate target proteins;Metabolism of proteins;SUMOylation (Consensus)

Recessive Scores

pRec
0.416

Haploinsufficiency Scores

pHI
0.165
hipred
hipred_score
ghis
0.458

Essentials

essential_gene_CRISPR
N
essential_gene_CRISPR2
N
essential_gene_gene_trap
N
gene_indispensability_pred
E
gene_indispensability_score
0.953

Gene Damage Prediction

AllRecessiveDominant
MendelianMediumMediumMedium
Primary ImmunodeficiencyMediumMediumMedium
CancerMediumMediumMedium

Mouse Genome Informatics

Gene name
Foxl2
Phenotype
reproductive system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); normal phenotype; vision/eye phenotype; homeostasis/metabolism phenotype; endocrine/exocrine gland phenotype; growth/size/body region phenotype;

Zebrafish Information Network

Gene name
foxl2b
Affected structure
oocyte
Phenotype tag
abnormal
Phenotype quality
increased occurrence

Gene ontology

Biological process
negative regulation of transcription by RNA polymerase II;ovarian follicle development;oocyte growth;extraocular skeletal muscle development;apoptotic DNA fragmentation;regulation of transcription by RNA polymerase II;single fertilization;anatomical structure morphogenesis;female somatic sex determination;cell differentiation;positive regulation of luteinizing hormone secretion;positive regulation of apoptotic process;positive regulation of cysteine-type endopeptidase activity involved in apoptotic process;negative regulation of transcription, DNA-templated;positive regulation of transcription, DNA-templated;positive regulation of transcription by RNA polymerase II;positive regulation of follicle-stimulating hormone secretion;embryonic eye morphogenesis;granulosa cell differentiation;uterus development
Cellular component
nucleus;nucleoplasm;intercellular bridge
Molecular function
RNA polymerase II proximal promoter sequence-specific DNA binding;DNA-binding transcription factor activity, RNA polymerase II-specific;DNA-binding transcription activator activity, RNA polymerase II-specific;DNA binding;DNA-binding transcription factor activity;protein binding;estrogen receptor binding;ubiquitin conjugating enzyme binding;cysteine-type endopeptidase regulator activity involved in apoptotic process